EA201490911A1 - Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина - Google Patents
Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидинаInfo
- Publication number
- EA201490911A1 EA201490911A1 EA201490911A EA201490911A EA201490911A1 EA 201490911 A1 EA201490911 A1 EA 201490911A1 EA 201490911 A EA201490911 A EA 201490911A EA 201490911 A EA201490911 A EA 201490911A EA 201490911 A1 EA201490911 A1 EA 201490911A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- treatment
- cytidine
- disorders
- malignant tumors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- UHDGCWIWMRVCDJ-XVFCMESISA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 abstract 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 210000000777 hematopoietic system Anatomy 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554344P | 2011-11-01 | 2011-11-01 | |
| PCT/US2012/062845 WO2013067043A1 (en) | 2011-11-01 | 2012-10-31 | Methods for treating cancers using oral formulations of cytidine analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201490911A1 true EA201490911A1 (ru) | 2014-09-30 |
Family
ID=47146759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490911A EA201490911A1 (ru) | 2011-11-01 | 2012-10-31 | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9125884B2 (enExample) |
| EP (1) | EP2773322A1 (enExample) |
| JP (1) | JP6162709B2 (enExample) |
| KR (1) | KR20140088603A (enExample) |
| CN (1) | CN104168884A (enExample) |
| AU (1) | AU2012318239B2 (enExample) |
| BR (1) | BR112014010417A2 (enExample) |
| CA (1) | CA2853949A1 (enExample) |
| EA (1) | EA201490911A1 (enExample) |
| HK (1) | HK1200716A1 (enExample) |
| IL (1) | IL232268A0 (enExample) |
| MX (1) | MX2014005314A (enExample) |
| PH (1) | PH12014500965A1 (enExample) |
| SG (1) | SG11201401946QA (enExample) |
| TW (2) | TWI558401B (enExample) |
| WO (1) | WO2013067043A1 (enExample) |
| ZA (2) | ZA201403106B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009246926B2 (en) | 2008-05-15 | 2014-06-26 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| MY176125A (en) | 2011-11-03 | 2020-07-24 | Takeda Pharmaceuticals Co | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
| WO2015107105A1 (en) * | 2014-01-15 | 2015-07-23 | Apogenix Gmbh | Method of predicting the responsiveness of a cancer disease to treatment on the basis of DNA methylation |
| WO2015195634A1 (en) * | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| WO2015195786A2 (en) * | 2014-06-17 | 2015-12-23 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| CN104147036B (zh) * | 2014-08-24 | 2017-04-05 | 浙江大学 | 地西他滨和奥沙利铂在制备治疗肾细胞癌组合药物中应用 |
| TWI716415B (zh) | 2015-06-29 | 2021-01-21 | 日商大賽璐股份有限公司 | 易服用性固態製劑之製造方法及易服用性固態製劑 |
| TWI690333B (zh) * | 2015-06-29 | 2020-04-11 | 日商大賽璐股份有限公司 | 易服用性固態製劑（有核錠）之製造方法及易服用性固態製劑 |
| WO2017037022A1 (en) * | 2015-09-01 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Compounds and methods useful for treating or preventing hematological cancers |
| EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| WO2017180768A1 (en) * | 2016-04-15 | 2017-10-19 | Seattle Genetics, Inc. | Combinations of cd33 antibody drug conjugates with hypomethylating agents |
| US11110179B2 (en) | 2016-06-03 | 2021-09-07 | Seagen Inc. | Combination of CD33 antibody drug conjugates with chemotherapeutic agents |
| IL262565B (en) * | 2016-06-06 | 2022-08-01 | Celgene Corp | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| EP3469001A4 (en) | 2016-06-09 | 2020-05-06 | Seattle Genetics, Inc. | COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS |
| US12359257B2 (en) | 2016-07-06 | 2025-07-15 | Helio Health Inc. | Liver cancer methylation markers and uses thereof |
| JP7239181B2 (ja) | 2017-04-04 | 2023-03-14 | ロマ リンダ ユニヴァーシティ | 癌治療のための生物製剤 |
| GB201819453D0 (en) * | 2018-11-29 | 2019-01-16 | Ucl Business Plc | Molecular signature |
| JP7767279B2 (ja) * | 2019-11-04 | 2025-11-11 | ジェロン・コーポレーション | 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 |
| WO2023140691A1 (ko) * | 2022-01-21 | 2023-07-27 | 주식회사 피노바이오 | 5-아자-4'-티오-2'-데옥시사이티딘을 함유하는 경구용 제형 및 이의 제조방법 |
| KR20240139581A (ko) * | 2023-03-14 | 2024-09-23 | 주식회사 피노바이오 | 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| PT998271E (pt) | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| PT1251832E (pt) | 2000-02-04 | 2007-01-31 | Depomed Inc | Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| EP1556010A4 (en) | 2002-10-31 | 2007-12-05 | Supergen Inc | PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS |
| EP2359859A1 (en) | 2002-12-09 | 2011-08-24 | Abraxis BioScience, LLC | Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents |
| US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| CA2598239C (en) | 2005-02-18 | 2019-10-29 | Abraxis Bioscience, Inc. | Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| DK2117520T3 (en) | 2006-12-14 | 2019-01-07 | Abraxis Bioscience Llc | BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN |
| WO2008092127A1 (en) | 2007-01-25 | 2008-07-31 | Nevada Cancer Institute | Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents |
| US8399420B2 (en) | 2007-09-26 | 2013-03-19 | Mount Sanai School of Medicine | Azacytidine analogues and uses thereof |
| CA2742252A1 (en) | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| RU2010145529A (ru) | 2008-04-10 | 2012-05-20 | АБРАКСИС БАЙОСАЙЕНС ЭлЭлСи (US) | Композиции гидрофобных производных таксана и их применение |
| MX2010011165A (es) | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| AU2009246926B2 (en) * | 2008-05-15 | 2014-06-26 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| KR20170015525A (ko) * | 2008-11-22 | 2017-02-08 | 제넨테크, 인크. | 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도 |
| WO2010093435A1 (en) | 2009-02-10 | 2010-08-19 | Celgene International Sarl | Methods for treating non-small cell lung cancer using 5-azacytidine |
| MY166014A (en) | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| WO2013022872A1 (en) | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
-
2012
- 2012-10-31 HK HK15101233.8A patent/HK1200716A1/xx unknown
- 2012-10-31 US US13/665,778 patent/US9125884B2/en not_active Expired - Fee Related
- 2012-10-31 EA EA201490911A patent/EA201490911A1/ru unknown
- 2012-10-31 CA CA2853949A patent/CA2853949A1/en not_active Withdrawn
- 2012-10-31 JP JP2014540046A patent/JP6162709B2/ja active Active
- 2012-10-31 TW TW101140377A patent/TWI558401B/zh not_active IP Right Cessation
- 2012-10-31 WO PCT/US2012/062845 patent/WO2013067043A1/en not_active Ceased
- 2012-10-31 BR BRBR112014010417-4A patent/BR112014010417A2/pt not_active Application Discontinuation
- 2012-10-31 CN CN201280065749.3A patent/CN104168884A/zh active Pending
- 2012-10-31 EP EP12783817.5A patent/EP2773322A1/en not_active Withdrawn
- 2012-10-31 PH PH1/2014/500965A patent/PH12014500965A1/en unknown
- 2012-10-31 AU AU2012318239A patent/AU2012318239B2/en not_active Ceased
- 2012-10-31 TW TW105130025A patent/TW201700103A/zh unknown
- 2012-10-31 MX MX2014005314A patent/MX2014005314A/es not_active Application Discontinuation
- 2012-10-31 SG SG11201401946QA patent/SG11201401946QA/en unknown
- 2012-10-31 KR KR1020147014861A patent/KR20140088603A/ko not_active Withdrawn
-
2014
- 2014-04-27 IL IL232268A patent/IL232268A0/en unknown
- 2014-04-29 ZA ZA2014/03106A patent/ZA201403106B/en unknown
-
2015
- 2015-04-16 US US14/688,623 patent/US9693987B2/en active Active
- 2015-04-28 ZA ZA2015/02909A patent/ZA201502909B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012318239B2 (en) | 2015-07-09 |
| ZA201502909B (en) | 2016-11-30 |
| AU2012318239A1 (en) | 2013-05-16 |
| PH12014500965A1 (en) | 2014-06-30 |
| TWI558401B (zh) | 2016-11-21 |
| WO2013067043A1 (en) | 2013-05-10 |
| ZA201403106B (en) | 2015-08-26 |
| TW201700103A (zh) | 2017-01-01 |
| US20130109644A1 (en) | 2013-05-02 |
| JP2014532704A (ja) | 2014-12-08 |
| CA2853949A1 (en) | 2013-05-10 |
| SG11201401946QA (en) | 2014-05-29 |
| CN104168884A (zh) | 2014-11-26 |
| US9125884B2 (en) | 2015-09-08 |
| MX2014005314A (es) | 2014-09-08 |
| EP2773322A1 (en) | 2014-09-10 |
| BR112014010417A2 (pt) | 2014-11-18 |
| IL232268A0 (en) | 2014-06-30 |
| US20150216886A1 (en) | 2015-08-06 |
| HK1200716A1 (zh) | 2015-08-14 |
| US9693987B2 (en) | 2017-07-04 |
| KR20140088603A (ko) | 2014-07-10 |
| TW201325598A (zh) | 2013-07-01 |
| NZ624323A (en) | 2016-07-29 |
| JP6162709B2 (ja) | 2017-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
| MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
| MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| PH12019500025A1 (en) | Cancer treatment combinations | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| IN2012DN06720A (enExample) | ||
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| BR112015010396A2 (pt) | terapia de combinação | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| BR112012016543A2 (pt) | Tratamento com vb-201 | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| RU2015105821A (ru) | Способ адъювантного лечения рака | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| BR112016023450A2 (pt) | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce | |
| UY33219A (es) | Cetoenoles cíclicos para terapias | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| BR112018011196A2 (pt) | uso de pirimido-pirimidazinonas para tratar o câncer | |
| SG194753A1 (en) | Induction of il-12 using immunotherapy | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| WO2015195786A3 (en) | Methods for treating cancers using oral formulations of cytidine analogs | |
| BR112015002384A2 (pt) | combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa | |
| RU2011108787A (ru) | Способ лечения больных красным плоским лишаем слизистой полости рта | |
| RU2014150506A (ru) | Велипариб в комбинации с лучевой терапией всего мозга для лечения метастазов в головной мозг |